A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors
Authors:
Open Access
- 1 June 2016
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (24) , 12724-12731
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response studyInternational Journal of General Medicine, 2013
- Identification of Key Residues Determining Species Differences in Inhibitor Binding of Microsomal Prostaglandin E Synthase-1*Journal of Biological Chemistry, 2010
- Molecular Modelling of CYP2F Substrates: Comparison of Naphthalene Metabolism by Human, Rat and Mouse CYP2F Subfamily EnzymesDrug Metabolism and Drug Interactions, 2009
- MF63 [2-(6-Chloro-1 H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of InflammationThe Journal of Pharmacology and Experimental Therapeutics, 2008
- What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseasesTrends in Pharmacological Sciences, 2008
- Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating ProteinScience, 2007
- Humanized mice in translational biomedical researchNature Reviews Immunology, 2007
- Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005Thorax, 1997
- Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesisNature, 1990
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973